The global market for Sustained Release Excipients was valued at US$1.7 Billion in 2024 and is projected to reach US$2.4 Billion by 2030, growing at a CAGR of 6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Global Sustained Release Excipients Market - Key Trends and Drivers Summarized
How Are Sustained Release Excipients Enhancing Drug Delivery?
Sustained release excipients are critical components in pharmaceutical formulations designed to control the release of active ingredients over an extended period. These excipients help maintain consistent drug levels in the bloodstream, improving therapeutic effectiveness while reducing side effects and dosing frequency. Commonly used in oral tablets, capsules, injectables, and transdermal patches, sustained release excipients support various therapeutic areas, including pain management, cardiovascular diseases, and mental health treatments. As pharmaceutical companies focus on improving patient adherence and drug efficacy, sustained release formulations have gained prominence, making excipients vital in drug development.What Are the Key Segments in the Sustained Release Excipients Market?
Key types include polymers, lipids, and carbohydrates, with polymers holding the largest market share due to their versatility, safety, and effectiveness in controlling drug release. Applications cover pain management, cardiovascular treatment, diabetes management, and CNS disorders, with pain management representing a significant segment driven by the need for consistent drug delivery to alleviate chronic pain. Formulations include tablets, capsules, injectables, and transdermal patches, with tablets leading the market due to their widespread use, cost-effectiveness, and patient acceptance.How Are Sustained Release Excipients Integrated Across Drug Development?
In pain management, sustained release excipients help maintain steady analgesic levels, reducing dosing frequency and improving patient compliance. In cardiovascular treatments, excipients support consistent blood pressure and cholesterol control, reducing the risk of adverse events associated with peak concentrations. For diabetes management, sustained release formulations aid in stabilizing blood glucose levels, providing better glycemic control. Additionally, in mental health treatments, excipients ensure stable drug release, improving outcomes in depression, anxiety, and bipolar disorder management by maintaining consistent therapeutic levels.What Factors Are Driving the Growth in the Sustained Release Excipients Market?
The growth in the Sustained Release Excipients market is driven by several factors, including increasing demand for controlled-release drug formulations, advancements in excipient technology, and a focus on improving patient adherence. Innovations like multifunctional excipients, better bioavailability, and enhanced safety profiles have supported broader adoption across therapeutic areas. The focus on reducing dosing frequency, managing side effects, and achieving optimal therapeutic outcomes has further fueled demand, as sustained release excipients play a crucial role in achieving these goals. Additionally, growing investments in drug development, expanding chronic disease management, and regulatory support for sustained release drugs have contributed to market growth, encouraging the use of excipients across pharmaceutical formulations.Report Scope
The report analyzes the Sustained Release Excipients market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments
Product Segment (Polymers, Sugars, Alcohol, Gelatin, Other Product Segments).Geographic Regions/Countries
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.Key Insights:
- Market Growth: Understand the significant growth trajectory of the Polymers segment, which is expected to reach US$1.2 Billion by 2030 with a CAGR of a 6.7%. The Sugars segment is also set to grow at 5.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $463.8 Million in 2024, and China, forecasted to grow at an impressive 5.6% CAGR to reach $370.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Alkermes plc, Allergan plc, Aradigm Corporation, AstraZeneca, Capsugel and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Sustained Release Excipients Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sustained Release Excipients Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Sustained Release Excipients Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Some of the 43 major companies featured in this Sustained Release Excipients market report include:
- Alkermes plc
- Allergan plc
- Aradigm Corporation
- AstraZeneca
- Capsugel
- Coating Place, Inc.
- Corium International, Inc.
- Depomed, Inc.
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc.
- Mayne Pharma Group Limited
- Mylan N.V.
- Novartis AG
- Orbis Biosciences, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International, Inc.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alkermes plc
- Allergan plc
- Aradigm Corporation
- AstraZeneca
- Capsugel
- Coating Place, Inc.
- Corium International, Inc.
- Depomed, Inc.
- GlaxoSmithKline plc
- Janssen Pharmaceuticals, Inc.
- Mayne Pharma Group Limited
- Mylan N.V.
- Novartis AG
- Orbis Biosciences, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Valeant Pharmaceuticals International, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 94 |
| Published | February 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 1.7 Billion |
| Forecasted Market Value ( USD | $ 2.4 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
